Otamixaban
- Generic Name
- Otamixaban
- Drug Type
- Small Molecule
- Chemical Formula
- C25H26N4O4
- CAS Number
- 193153-04-7
- Unique Ingredient Identifier
- S173RED00L
- Background
Otamixaban is a novel direct Factor Xa (FXa) inhibitor. It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.
- Indication
Investigated for use/treatment in thrombosis.
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild and Moderate Hepatic Impairment
- First Posted Date
- 2010-05-19
- Last Posted Date
- 2014-05-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 25
- Registration Number
- NCT01126086
- Locations
- πΊπΈ
Investigational Site Number 840001, Orlando, Florida, United States
πΊπΈInvestigational Site Number 840002, Knoxville, Tennessee, United States
πΊπΈInvestigational Site Number 840003, Miami Gardens, Florida, United States
Pharmacokinetic, Pharmacodynamic and Tolerability Study of Otamixaban in Patients With Mild, Moderate and Severe Renal Impairment
- First Posted Date
- 2010-05-10
- Last Posted Date
- 2014-05-12
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 48
- Registration Number
- NCT01120314
- Locations
- πΊπΈ
Investigational Site Number 840003, Miami Gardens, Florida, United States
πΊπΈInvestigational Site Number 840004, St. Paul, Minnesota, United States
πΊπΈInvestigational Site Number 840005, Orlando, Florida, United States
Effect of Otamixaban Versus Unfractionated Heparin + Eptifibatide in Patients With Unstable Angina/Non ST Elevation Myocardial Infarction Undergoing Early Invasive Strategy
- Conditions
- Acute Coronary Syndrome
- Interventions
- Drug: Placebo (for Otamixaban)Drug: Placebo (for UFH)Drug: UFHDrug: Placebo (for Eptifibatide)
- First Posted Date
- 2010-02-26
- Last Posted Date
- 2016-05-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 13220
- Registration Number
- NCT01076764
- Locations
- πΊπΈ
Investigational Site Number 840911, Pittsburgh, Pennsylvania, United States
π¦π·Investigational Site Number 032010, Cordoba, Argentina
π¦π·Investigational Site Number 032020, Mendoza, Argentina
Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome
- Conditions
- Coronary Disease
- Interventions
- First Posted Date
- 2006-04-24
- Last Posted Date
- 2014-12-03
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3241
- Registration Number
- NCT00317395
- Locations
- πΉπ·
Sanofi-Aventis Administrative Office, Istanbul, Turkey
The SEPIA-PCI Trial: Otamixaban in Comparison to Heparin in Subjects Undergoing Non-Urgent Percutaneous Coronary Intervention
- Conditions
- Angioplasty, Transluminal, Percutaneous Coronary
- First Posted Date
- 2005-08-24
- Last Posted Date
- 2008-07-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 947
- Registration Number
- NCT00133731
- Locations
- πΊπΈ
Los Angeles Cardiology Associates, Los Angeles, California, United States
πΊπΈRush University Medical Center, Chicago, Illinois, United States
πΊπΈThe Cleveland Clinic Foundation, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.